Recursion Pharmaceuticals, Inc. Stock Price, News & Analysis

Recursion (RXRX) reported significant clinical and financial updates for Q2 2022, advancing multiple trials including Phase 2/3 for NF2-mutated meningiomas and a Phase 2 for Familial Adenomatous Polyposis (FAP). The FDA granted Fast Track and European Commission granted Orphan Drug designations for REC-4881, supporting its potential FAP treatment. Revenue rose to $7.7 million, up from $2.5 million in Q2 2021, driven by collaborations. However, R&D costs increased to $38.4 million, and the company reported a net loss of $65.6 million, overshadowing revenue growth.

Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company, announced its participation in the KeyBanc Technology Leadership Forum from August 8 to August 9, 2022. The company's innovative approach utilizes advanced machine learning and extensive biological datasets to transform drug discovery. Based in Salt Lake City, Recursion is a key player in the life sciences sector, significantly enhancing pharmaceutical research through its Recursion OS platform. For further information, visit www.recursion.com.

Recursion (NASDAQ: RXRX) announced that the European Commission granted Orphan Drug Designation for REC-4881, aimed at treating familial adenomatous polyposis (FAP). REC-4881 is a small molecule MEK1 and MEK2 inhibitor, designed to reduce polyp burden in FAP patients. Currently, there are no approved therapies for FAP, which affects about 50,000 patients in the US and Europe. This designation follows similar approvals by the FDA, helping to advance REC-4881 towards a Phase 2 clinical trial by the end of Q3 2022.

Recursion (NASDAQ: RXRX) has launched the Phase 2/3 POPLAR-NF2 clinical trial for REC-2282, targeting NF2-mutated meningiomas, a condition affecting approximately 33,000 patients annually. The trial, which is randomized and placebo-controlled, expects to enroll around 90 participants, assessing REC-2282's safety and efficacy. This compound has received both Fast Track and Orphan Drug designations from the FDA and the European Commission, positioning it as a potential first-in-class treatment for these debilitating tumors.

Recursion (NASDAQ: RXRX), a biotechnology firm focused on drug discovery, announced its engagement in three upcoming investor conferences. These include the Jefferies Healthcare Conference from June 8 to June 10, 2022, the Goldman Sachs Annual Global Healthcare Conference from June 13 to June 16, 2022, and Morgan Stanley's Putting the Tech in Biotech Conference on June 28, 2022. The company utilizes advanced machine-learning algorithms to enhance drug discovery through its proprietary Recursion Operating System, expanding its extensive biological and chemical datasets.

Recursion (Nasdaq: RXRX) announced significant advancements in its clinical trials and financial results for Q1 2022. The company initiated dosing in its Phase 2 trial for cerebral cavernous malformation (CCM) and plans to start a Phase 2/3 trial for NF2-mutated meningiomas in Q2 2022. REC-4881 received Fast Track designation for familial adenomatous polyposis (FAP), with a Phase 2 trial set for Q3 2022. Financially, Q1 2022 revenues reached $5.3 million, up from $2.6 million year-over-year, although R&D expenses rose to $32.4 million, contributing to a net loss of $56.0 million.

Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company, has announced its participation in the Bank of America 2022 Healthcare Conference, taking place from May 10 to May 13, 2022. This event will showcase Recursion's innovative approach to drug discovery through its Recursion Operating System, which integrates advanced technologies and vast datasets. Recursion aims to transform medicine by leveraging machine learning and running millions of experiments weekly. Webcasts will be available on the company's investor website.

Recursion (NASDAQ: RXRX) has received FDA Fast Track designation for its drug candidate REC-4881, aimed at treating familial adenomatous polyposis (FAP) in patients post-colectomy. This allosteric small molecule inhibitor targets MEK1 and MEK2, intended to reduce polyp burden and prevent progression to adenocarcinoma. The designation facilitates expedited drug review, enabling earlier access for patients upon approval. A Phase 2 trial for REC-4881 is set to enroll patients in Q3 2022, marking a significant step towards addressing the unmet needs in FAP treatment.

Recursion (NASDAQ: RXRX), a clinical-stage biotechnology firm, announced its participation in three upcoming investor conferences. These include the Piper Sandler AI/Machine Learning Conference on April 1, 2022, the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022, and the Berenberg Discover AI Seminar 2022 on April 26, 2022. The conferences are aimed at showcasing Recursion's advancements in drug discovery, leveraging its extensive biological and chemical datasets. Interested parties can access live webcasts via the investor section of Recursion's website.